Company: SMNR
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001193125-25-306962
Chunk: 11

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 11
---
 2025. We expect to continue to make investments in research and development, clinical trials and regulatory affairs to develop our product candidate, SP-102.

We have completed a pivotal Phase 3 study with final results received in March 2022, which results reflected achievement of primary and
secondary endpoints, with SP-102 treatment decreasing pain intensity for over a month in sciatica patients and resulting in statistically significant and clinically meaningful improvement in the disability index score while maintaining tolerability
comparable to placebo. The Phase 3 study results were published in PAIN Journal in June 2024, which is the leading journal devoted to pain medicine and research. This Phase 3 study represents
a potential significant improvement in treatment of adult patients with sciatica, who struggle with the clinical consequences of no currently FDA approved therapies being available, suboptimal formulations of corticosteroids used off-label and/or
excess pain and disability. We initiated a second Phase 3 study in September 2025.

Our guiding principle has always been and remains a
patient-first approach, which drives its mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions. Through rigorous research and development, we
believe Semnur is on the cusp of establishing itself as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with its innovative and leading therapies. We believe
that Semnur has made substantial progress in demonstrating the rapid onset and enhanced tolerability of its product candidate.

Principal Executive Offices and Additional Information

Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303,
and our telephone number is (650) 516-4310. Our website address iswww.semnurpharma.com. Any information contained on, or that can be accessed through, our website is not incorporated by
reference into, nor is it in any way part of this Reoffer Prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports,
proxy statements and other information with the Commission. You may obtain any of the documents filed by us with the Commission at no cost from the Commission’s website at http://www.sec.gov.

The Offering

This Reoffer Prospectus
relates to the public offering, which is not being underwritten, by the Selling Stockholders listed in this Reoffer Prospect